Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 445 (CSE: $CURA.C)
(TSXV: $KHRN.V) (TSX: $FAF.TO) (TSX: $LABS.TO) (OTCQB: $TECR)
Delta, Kelowna, BC, July 23, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at http://www.investorideas.com/news/2020/cannabis-potcasts/07231CURA-KHRN-FAF-LABS-TECR.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Curaleaf
Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF), the largest vertically integrated cannabis operator
in the United States, today
announced that it closed its milestone acquisition of GR
Companies, Inc., the largest private vertically-integrated multi-state operator
in the United States, on July 23, 2020.
With completion of the acquisition
of Grassroots, Curaleaf is the world's largest cannabis company by revenue and
the most diversified vertically integrated cannabis company in the United
States, the world's largest cannabis market. The transaction expands Curaleaf's
presence from 18 to 23 states, with the combined company having affiliated
operations spanning over 135 dispensary licenses, 88 operational dispensary
locations, over 30 processing facilities and 22 cultivation sites with 1.6
million square feet of current cultivation capacity. Curaleaf's expanded
geographic dispensary presence now offers access to medical or adult use
Cannabis to more than 192 million people, or roughly two-thirds of the United
States population.
"The successful acquisition of
Grassroots marks Curaleaf's expansion into new vertically integrated markets in
the Midwest, firmly establishing our U.S. market leadership position. This
highly complementary combination brings together two companies with a shared
vision for enhancing patients' and customers' lives with high-quality cannabis
wellness and lifestyle products. I'd like to welcome all our new Grassroots
colleagues, patients and customers to the Curaleaf family as we pursue our
mission of improving lives by providing clarity around cannabis and confidence
around consumption," commented Joseph Lusardi, CEO of Curaleaf. "The
integration of Grassroots is expected to be immediately accretive to our
financial performance, with our unprecedented scale providing significant
opportunities to leverage Curaleaf's powerful consumer brands as well as new
form factor innovations across our expanded national presence."
Completion of the transaction
strategically accelerates Curaleaf's expansion into Illinois and Pennsylvania,
which are among the largest and fastest-growing cannabis markets in the United
States. Upon close, Curaleaf will hold a leading licensed cannabis presence in
state markets including Arizona, Connecticut, Florida, Illinois, Pennsylvania,
Maryland, Massachusetts, Maine, Nevada, New Jersey, New York, North Dakota, and
Vermont.
The cultivation and processing
assets in Illinois have been transferred and the formal approval to transfer
certain retail assets is expected imminently. Maryland operations previously
affiliated with Grassroots may be transferred to Curaleaf after expiration of
the statutory hold period, subject to regulatory approval and compliance with
restrictions on ownership or control of multiple cultivation, processor and
dispensary licenses in the State.
Khiron
Life Sciences Corp. (TSXV:
KHRN) (OTCQX:
KHRNF), a vertically integrated cannabis leader with core
operations in Latin America and Europe, announced
today that it has received import licenses and all necessary
authorizations from the Directorate
General of Drug Supplies and Drugs (DIGEMID) for the import and
commercialization of full spectrum, high-CBD medical cannabis products from
Khiron Colombia into Peru.
"Successfully completing all
licensing, import and distribution requirements allows us to bring our full
spectrum, high CBD medical cannabis products into Peru. We have an experienced
country management team in place in Lima and, together with our distribution
partner Farmacia Universal, are now positioned to give patients in Peru greater
access to medical cannabis therapies. Additionally, we anticipate fulfilling
all necessary requirements to commercialize high-THC medical cannabis products
in Peru during Q4 2020," comments Luis Marquez, Khiron Peru Country
Manager.
In Peru, only registered
pharmaceutical establishments that have received Good Storage Practices (GSP)
certification are authorized to participate in the wholesale import and
commercialization of cannabis products. Khiron Peru is a GSP certified,
registered pharmaceutical establishment, and Farmacia Universal has all
required permits, including Good Manufacturing Practices (GMP) certification,
to distribute medical cannabis final products to patients through pharmacies
under the previously announced agreement with Khiron.
With receipt of the final licenses
and authorizations from DIGEMID, Khiron Peru is now fully authorized to import
full spectrum, high-CBD medical cannabis from Khiron Colombia, which is now
fully authorized by the Narcotics National Fund (NNF) in Colombia for the
export to Peru. The Company anticipates prescriptions can be filled commencing
in Q3 2020.
"Entry to the Peru medical
cannabis market continues our relentless focus on meeting patient needs in
Latin America and globally. We are currently the only company in Colombia that
has dispensed medical cannabis to patients and have now surpassed our first
1,000 medical cannabis patient prescriptions milestone. This, despite a global
pandemic that has slowed down many of the world's economies, represents a very
important achievement for us," comments Alvaro Torres, Khiron CEO and
director.
Fire
& Flower Holdings Corp. and its wholly-owned subsidiary Fire &
Flower Inc. (TSX:
FAF)
(OTCQX:
FFLWF), today
announced that it has received the Approval in Principle from
the Liquor and Cannabis Regulation Branch of the province of British Columbia
for two cannabis retail stores located in Vancouver, British Columbia.
Receiving the AIP is one of the
final steps required for licensing cannabis retail stores in the province of
British Columbia, and the receipt of the AIPs presents a clearer path for the
Company's entry into this new market.
The AIPs come upon the LCRB
completing its eligibility and suitability assessment of Fire & Flower and
the Company was found to be "fit and proper" for the purposes of
receiving final licenses upon satisfactory inspection of the finished stores in
accordance with the AIPs.
"Fire & Flower is very
pleased to be entering the province of British Columbia in the key urban market
of Vancouver. We have been poised to launch stores in the province for some
time as part of our national growth strategy," shared Trevor Fencott,
Chief Executive Officer of Fire & Flower. "It is encouraging to see
the province of British Columbia move forward with additional cannabis retail
licenses. The issuance of additional licenses is a key step in the eradication
of the illicit cannabis market and licensing in the province is an important
step in the growth of the legal cannabis industry."
Once opened, the Vancouver Fire
& Flower stores will be located at:
● 2231
Granville Street, Vancouver, British Columbia, and
● 2570
Granville Street, Vancouver, British Columbia.
Opening dates and times of the
Vancouver Fire & Flower stores will be announced on the Company's website
at www.fireandflower.com/locations/ and
through social media at the earliest opportunity.
MediPharm
Labs Corp. (TSX:
LABS) (OTCQX:
MEDIF) today
announced its Australian operation – MediPharm Labs Australia Pty. Ltd. – has reached its first month
operational milestone, with approximately $500,000 AUD, of formulated products
delivered to customers in Australia, on its way to developing a strong
commercial presence in international markets.
“MediPharm Labs Australia was
conceived as a part of our strategy to develop a multi-jurisdictional,
GMP-certified production capability for worldwide medicinal, wellness and
adult-use markets and since opening at the end of 2019, it has signed a number
of significant domestic and international customer supply agreements,” said Pat
McCutcheon, Chief Executive Officer, MediPharm Labs. “To reach this revenue
milestone this quickly – in fact just two months after receiving Australian GMP
certification – is positive proof of the demand for our capabilities and
formulations and that our international team is beginning to hit its stride. I
congratulate my colleagues in Australia for what will be the first of many
milestone accomplishments.”
The Company’s Australian facility
was certified by the Therapeutic Goods Administration as meeting the GMP
standard and secured a Licence to Manufacture Therapeutic Goods in May 2020. As
the Company’s Canadian facility was TGA GMP certified in late 2019, MediPharm
Labs has created a global pharmaceutical-quality supply chain that is qualified
to serve new emerging medical markets internationally.
“Speaking on behalf of our local
team, we couldn’t be more excited by this development and the long-term
potential we have to lead our markets,” said Warren Everitt, CEO, Asia Pacific,
MediPharm Labs. “Our first month of operations included shipments of
approximately $500,000 AUD comprising formulated CBD and THC oils that our
customers can trust for quality and reliability. These shipments are the
product of synergies between our Canadian and Australian facilities as they
were made possible by a large shipment of finished products and bulk oil from
our sister GMP-certified facility in Barrie, Ontario. We intend to continue
taking advantage of our internal supply pipeline on a strategic basis as we
expand our international market share.”
On July 21, 2020, the board of
directors of Citrine Global Corp. (OTCQB:
TECR) approved for its wholly-owned Israeli subsidiary CTGL - Citrine Global Israel Ltd. to
take part in a joint venture for the
establishment of a “Cannovation Center” - Cannabis Innovation Center - in
Israel to address the needs of the emerging cannabis, CBD and hemp industry.
CTGL - Citrine Global Israel Ltd will hold around 60% of the Cannovation
Center.
The Cannovation Center is a unique,
all-in-one platform with factories for producing cannabis, hemp and CBD
products, laboratories and a logistics and distribution center, for supporting
the cannabis eco-system, including cannabis growers, cannabis product
developers, researchers and businesses, that operate in a field that requires
interdisciplinary professional expertise and compliance with a wide set of
regulatory demands, including IMC-GMP production standards, 24/7 surveillance
and security, special recycling procedures, and more.
The Cannovation Center in Israel
will provide solutions for companies in Israel and worldwide, leveraging Israel’s
leadership in cannabis innovation and promoting the production and distribution
of cannabis, hemp and CBD products for local and global markets.
The Cannovation Center is in the
process of obtaining a government grant. The Israeli Government provides grants
and subsidies specific to the cannabis industry as part of its strategy for
boosting the economy through technological innovation.
Ora Meir Soffer, Citrine Global's
Chairperson and CEO, stated: "Israel is a leading source of technological
innovation, including in the cannabis industry. Our Cannovation Center venture
is a result of years of involvement in the cannabis industry, and we are
confident that the Cannovation Center will provide a solution for the needs of
the cannabis industry. We are happy that CTGL - Citrine Global Israel Ltd will
be a part of this. We hope this will be the first center, to be joined by
additional centers around the world".
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
